Evidence indicates that the immune response and antibody protection against respiratory syncytial virus (RSV) can wane rapidly over relatively short periods, contributing to frequent reinfections.
The claim is that the immune response to RSV is short-lived. Papers [2] and [5] directly support this by demonstrating rapid waning of RSV antibodies or discussing the short-lived nature of respiratory mucosal immunity leading to reinfection. Other papers discuss durability in different contexts (like nirsevimab passive immunization or vaccination), but do not refute the natural waning of active immunity described in the supporting literature.